Mortality rate and acute kidney injury prevalence reduction in COVID‑19 critical patients treated with hemoperfusion
Introduction: Coronavirus disease 2019 (COVID‑19) induces organic damage mainly through the patient’s immune overreaction. Hemoperfusion (HPF) can remove infl ammatory cytokines and can reduce the negative effects of cytokine storm in COVID‑19. We compared the mortality rate, infl ammatory response,...
- Autores:
-
Barriga‑Moreno, Adriana P.
Lozano‑Sánchez, Marcela
Barón‑Álvarez, Rafael A.
Cordoba, Juan P.
Aroca‑Martínez, Gustavo
Dianda, Daniela
Gonzalez‑Torres, Henry
Musso, Carlos G.
- Tipo de recurso:
- Fecha de publicación:
- 2024
- Institución:
- Universidad Simón Bolívar
- Repositorio:
- Repositorio Digital USB
- Idioma:
- eng
- OAI Identifier:
- oai:bonga.unisimon.edu.co:20.500.12442/14485
- Acceso en línea:
- https://hdl.handle.net/20.500.12442/14485
- Palabra clave:
- Acute kidney injury
COVID‑19
Hemoperfusion
- Rights
- openAccess
- License
- Attribution-NonCommercial-NoDerivatives 4.0 Internacional
id |
USIMONBOL2_dc46da2fdf5e0d612abba603fc5522c0 |
---|---|
oai_identifier_str |
oai:bonga.unisimon.edu.co:20.500.12442/14485 |
network_acronym_str |
USIMONBOL2 |
network_name_str |
Repositorio Digital USB |
repository_id_str |
|
dc.title.eng.fl_str_mv |
Mortality rate and acute kidney injury prevalence reduction in COVID‑19 critical patients treated with hemoperfusion |
title |
Mortality rate and acute kidney injury prevalence reduction in COVID‑19 critical patients treated with hemoperfusion |
spellingShingle |
Mortality rate and acute kidney injury prevalence reduction in COVID‑19 critical patients treated with hemoperfusion Acute kidney injury COVID‑19 Hemoperfusion |
title_short |
Mortality rate and acute kidney injury prevalence reduction in COVID‑19 critical patients treated with hemoperfusion |
title_full |
Mortality rate and acute kidney injury prevalence reduction in COVID‑19 critical patients treated with hemoperfusion |
title_fullStr |
Mortality rate and acute kidney injury prevalence reduction in COVID‑19 critical patients treated with hemoperfusion |
title_full_unstemmed |
Mortality rate and acute kidney injury prevalence reduction in COVID‑19 critical patients treated with hemoperfusion |
title_sort |
Mortality rate and acute kidney injury prevalence reduction in COVID‑19 critical patients treated with hemoperfusion |
dc.creator.fl_str_mv |
Barriga‑Moreno, Adriana P. Lozano‑Sánchez, Marcela Barón‑Álvarez, Rafael A. Cordoba, Juan P. Aroca‑Martínez, Gustavo Dianda, Daniela Gonzalez‑Torres, Henry Musso, Carlos G. |
dc.contributor.author.none.fl_str_mv |
Barriga‑Moreno, Adriana P. Lozano‑Sánchez, Marcela Barón‑Álvarez, Rafael A. Cordoba, Juan P. Aroca‑Martínez, Gustavo Dianda, Daniela Gonzalez‑Torres, Henry Musso, Carlos G. |
dc.subject.eng.fl_str_mv |
Acute kidney injury COVID‑19 Hemoperfusion |
topic |
Acute kidney injury COVID‑19 Hemoperfusion |
description |
Introduction: Coronavirus disease 2019 (COVID‑19) induces organic damage mainly through the patient’s immune overreaction. Hemoperfusion (HPF) can remove infl ammatory cytokines and can reduce the negative effects of cytokine storm in COVID‑19. We compared the mortality rate, infl ammatory response, and acute kidney injury (AKI) prevalence among patients suffering from respiratory insufficiency secondary to COVID‑19 treated with and without HPF with HA330 cartridge. Methods: Mortality rate, serum creatinine, and ferritin values were compared between patients suffering from respiratory insufficiency secondary to COVID‑19 who received conventional treatment and another group of patients who additionally received four sessions of HPF with HA330. Results: Of 116 patients suffering from acute respiratory insufficiency secondary to severe acute respiratory syndrome coronavirus 2 (SARS‑CoV‑2), one group (n: 84) received support treatment and the other group (n: 32) additionally received HPF with HA330 cartridge. Both groups had no renal disease and similar age and comorbidities at admission, except for obesity and mechanical ventilation requirement, which were significantly higher in the HPF group. Mortality rate (61% vs. 31%, P: 0.008), serum creatinine (1.4 vs. 0.5 mg/dl, P < 0.001), and post‑HPF serum ferritin (2868 vs. 1675, P < 0.001) were significantly lower in the HPF group. Conclusion: Mortality rate, serum ferritin, and AKI were significantly reduced in critical COVID‑19 patients who received HPF with HA330 cartridge than in those who did not receive it. These results were obtained despite the HPF group risk factors, such as obesity and mechanical ventilation, worsening its prognosis. |
publishDate |
2024 |
dc.date.accessioned.none.fl_str_mv |
2024-04-08T19:24:49Z |
dc.date.available.none.fl_str_mv |
2024-04-08T19:24:49Z |
dc.date.issued.none.fl_str_mv |
2024 |
dc.type.coarversion.fl_str_mv |
http://purl.org/coar/version/c_970fb48d4fbd8a85 |
dc.type.coar.fl_str_mv |
http://purl.org/coar/resource_type/c_2df8fbb1 |
dc.type.driver.spa.fl_str_mv |
info:eu-repo/semantics/article |
dc.type.spa.spa.fl_str_mv |
Artículo científico |
dc.identifier.citation.eng.fl_str_mv |
Barriga‑Moreno AP, Lozano‑Sanchez M, Barón‑Alvarez RA, Cordoba JP, Aroca‑Martinez G, Dianda D, et al. Mortality Rate and Acute Kidney Injury Prevalence Reduction in COVID‑19 Critical Patients Treated with Hemoperfusion. Indian J Nephrol 2024;34:56-8. doi: 10.4103/ijn.ijn_175_22 |
dc.identifier.issn.none.fl_str_mv |
09714065 |
dc.identifier.uri.none.fl_str_mv |
https://hdl.handle.net/20.500.12442/14485 |
dc.identifier.doi.none.fl_str_mv |
DOI: 10.4103/ijn.ijn_175_22 |
identifier_str_mv |
Barriga‑Moreno AP, Lozano‑Sanchez M, Barón‑Alvarez RA, Cordoba JP, Aroca‑Martinez G, Dianda D, et al. Mortality Rate and Acute Kidney Injury Prevalence Reduction in COVID‑19 Critical Patients Treated with Hemoperfusion. Indian J Nephrol 2024;34:56-8. doi: 10.4103/ijn.ijn_175_22 09714065 DOI: 10.4103/ijn.ijn_175_22 |
url |
https://hdl.handle.net/20.500.12442/14485 |
dc.language.iso.eng.fl_str_mv |
eng |
language |
eng |
dc.rights.*.fl_str_mv |
Attribution-NonCommercial-NoDerivatives 4.0 Internacional |
dc.rights.coar.fl_str_mv |
http://purl.org/coar/access_right/c_abf2 |
dc.rights.uri.*.fl_str_mv |
http://creativecommons.org/licenses/by-nc-nd/4.0/ |
dc.rights.accessrights.spa.fl_str_mv |
info:eu-repo/semantics/openAccess |
rights_invalid_str_mv |
Attribution-NonCommercial-NoDerivatives 4.0 Internacional http://creativecommons.org/licenses/by-nc-nd/4.0/ http://purl.org/coar/access_right/c_abf2 |
eu_rights_str_mv |
openAccess |
dc.format.mimetype.eng.fl_str_mv |
pdf |
dc.publisher.eng.fl_str_mv |
Wolters Kluwer |
dc.source.eng.fl_str_mv |
Indian Journal of Nephrology - IJN |
dc.source.none.fl_str_mv |
Vol. 34 No. 1, (2024) |
institution |
Universidad Simón Bolívar |
bitstream.url.fl_str_mv |
https://bonga.unisimon.edu.co/bitstreams/33d94629-7ad2-423d-947e-c0e2a29c1d1e/download https://bonga.unisimon.edu.co/bitstreams/fc609310-02a5-4167-8b22-39c09a1a463a/download https://bonga.unisimon.edu.co/bitstreams/d3c5f770-29df-437d-b6b7-71bf50898c7c/download https://bonga.unisimon.edu.co/bitstreams/dbc45d03-8d66-41d7-9cff-6de9b18b73d0/download https://bonga.unisimon.edu.co/bitstreams/f0629e4b-89d6-4e73-a7c5-8f2591178432/download https://bonga.unisimon.edu.co/bitstreams/060fb2c6-0e74-4ef5-8375-d4cbde4750a7/download https://bonga.unisimon.edu.co/bitstreams/d8f47a98-cf43-43bb-8e45-0872bde52b0d/download |
bitstream.checksum.fl_str_mv |
7040df93d50cbf1d900eba74463b06a1 4460e5956bc1d1639be9ae6146a50347 733bec43a0bf5ade4d97db708e29b185 17f6bb68a68136a4069a6f9234a0700d 17f6bb68a68136a4069a6f9234a0700d 8ed6de63ceec942325b41c3d9259e908 8ed6de63ceec942325b41c3d9259e908 |
bitstream.checksumAlgorithm.fl_str_mv |
MD5 MD5 MD5 MD5 MD5 MD5 MD5 |
repository.name.fl_str_mv |
Repositorio Digital Universidad Simón Bolívar |
repository.mail.fl_str_mv |
repositorio.digital@unisimon.edu.co |
_version_ |
1814076160086114304 |
spelling |
Barriga‑Moreno, Adriana P.02902934-8ba5-43e9-9389-b613daa5e458Lozano‑Sánchez, Marcelab38e8177-48aa-4e3a-8114-6675d9f1e80bBarón‑Álvarez, Rafael A.2b9b7e7b-d576-4f13-bc3a-37c3ad6d162eCordoba, Juan P.76e07f81-d542-4a51-8450-f2dfb06b1850Aroca‑Martínez, Gustavo2dc29dcb-55df-45d5-b5dd-dd282b9ece40Dianda, Daniela60417dd4-9cb5-4302-96a5-caf3ab281eabGonzalez‑Torres, Henry578aacf8-a19b-4d23-b54a-bedeb8f8a622Musso, Carlos G.e1f82fb4-05f8-40b4-8f34-3bd432a0baf42024-04-08T19:24:49Z2024-04-08T19:24:49Z2024Barriga‑Moreno AP, Lozano‑Sanchez M, Barón‑Alvarez RA, Cordoba JP, Aroca‑Martinez G, Dianda D, et al. Mortality Rate and Acute Kidney Injury Prevalence Reduction in COVID‑19 Critical Patients Treated with Hemoperfusion. Indian J Nephrol 2024;34:56-8. doi: 10.4103/ijn.ijn_175_2209714065https://hdl.handle.net/20.500.12442/14485DOI: 10.4103/ijn.ijn_175_22Introduction: Coronavirus disease 2019 (COVID‑19) induces organic damage mainly through the patient’s immune overreaction. Hemoperfusion (HPF) can remove infl ammatory cytokines and can reduce the negative effects of cytokine storm in COVID‑19. We compared the mortality rate, infl ammatory response, and acute kidney injury (AKI) prevalence among patients suffering from respiratory insufficiency secondary to COVID‑19 treated with and without HPF with HA330 cartridge. Methods: Mortality rate, serum creatinine, and ferritin values were compared between patients suffering from respiratory insufficiency secondary to COVID‑19 who received conventional treatment and another group of patients who additionally received four sessions of HPF with HA330. Results: Of 116 patients suffering from acute respiratory insufficiency secondary to severe acute respiratory syndrome coronavirus 2 (SARS‑CoV‑2), one group (n: 84) received support treatment and the other group (n: 32) additionally received HPF with HA330 cartridge. Both groups had no renal disease and similar age and comorbidities at admission, except for obesity and mechanical ventilation requirement, which were significantly higher in the HPF group. Mortality rate (61% vs. 31%, P: 0.008), serum creatinine (1.4 vs. 0.5 mg/dl, P < 0.001), and post‑HPF serum ferritin (2868 vs. 1675, P < 0.001) were significantly lower in the HPF group. Conclusion: Mortality rate, serum ferritin, and AKI were significantly reduced in critical COVID‑19 patients who received HPF with HA330 cartridge than in those who did not receive it. These results were obtained despite the HPF group risk factors, such as obesity and mechanical ventilation, worsening its prognosis.pdfengWolters KluwerAttribution-NonCommercial-NoDerivatives 4.0 Internacionalhttp://creativecommons.org/licenses/by-nc-nd/4.0/info:eu-repo/semantics/openAccesshttp://purl.org/coar/access_right/c_abf2Indian Journal of Nephrology - IJNVol. 34 No. 1, (2024)Acute kidney injuryCOVID‑19HemoperfusionMortality rate and acute kidney injury prevalence reduction in COVID‑19 critical patients treated with hemoperfusioninfo:eu-repo/semantics/articleArtículo científicohttp://purl.org/coar/version/c_970fb48d4fbd8a85http://purl.org/coar/resource_type/c_2df8fbb1Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID‑19 in Wuhan, China: A retrospective cohort Study. Lancet 2020;395:1054‑62.Ruan Q, Yang K, Wang W, Jiang L, Song J. Clinical predictors of mortality due to COVID‑19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med 2020;46:846‑8.Driggin E, Madhavan MV, Bikdeli B, Chuich T, Laracy J, Bondi‑Zoccai G, et al. Cardiovascular considerations for patients, health care workers, and health systems during the coronavirus disease 2019 (COVID‑19) pandemic. J Am Coll Cardiol 2020;75:2352‑71.Qin C, Zhou L, Hu Z, Zhang S, Yang S, Tao Y, et al. Dysregulation of immune response in patients with COVID‑19 in Wuhan, China. Clint Infect Dis 2020;71:762‑8.Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ. COVID‑19: Consider cytokine storm syndromes and immunosuppression. Lancet 2020;395:1033‑4.Pomarè‑Montin D, Ankawi G, Lorenzin A, Neri M, Caprara C, Ronco C. Biocompatibility and cytotoxic evaluation of new sorbent cartridges for blood hemoperfusion. Blood Purif 2018;46:187‑95.Ankawi G, Fan W, Pomarè Montin D, Lorenzin A, Neri M, Caprara C, et al. A new series of sorbent devices for multiple clinical purposes: Current evidence and future directions. Blood Purif 2019;47:94‑100.Rampino T, Gregorini M, Perotti L, Ferrari F, Pattonieri EF, Grignano MA, et al. Hemoperfusion with cytosorb as adjuvant therapy in critically ill patients with SARS‑CoV2 pneumonia. Blood Purif 2021;50:566‑71.Huang Z, Wang SR, Su W, Liu JY. Removal of humoral mediators and the effect on the survival of septic patients by hemoperfusion with neutral microporous resin column. Ther Apher Dial 2010;14:596‑602.He Z, Lu H, Jian X, Li G, Xiao D, Meng Q, et al. The efficacy of resin hemoperfusion cartridge on inflammatory responses during adult cardiopulmonary bypass. Blood Purif 2021;1‑7.Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus‑infected pneumonia in Wuhan, China. JAMA 2020;323:1061‑9.Ronco C, Bagshaw SM, Bellomo R, Clark WR, Husain‑Syed F, Kellum JA, et al. Extracorporeal blood purification and organ support in the critically ill patient during COVID‑19 pandemic: Expert review and recommendation. Blood Purif 2021;50:17‑27.Ronco C, Reis T. Kidney involvement in COVID‑19 and rationale for extracorporeal therapies. Nat Rev Nephrol 2020;16:308‑10.ORIGINALPDF.pdfPDF.pdfPDFapplication/pdf441790https://bonga.unisimon.edu.co/bitstreams/33d94629-7ad2-423d-947e-c0e2a29c1d1e/download7040df93d50cbf1d900eba74463b06a1MD51CC-LICENSElicense_rdflicense_rdfapplication/rdf+xml; charset=utf-8805https://bonga.unisimon.edu.co/bitstreams/fc609310-02a5-4167-8b22-39c09a1a463a/download4460e5956bc1d1639be9ae6146a50347MD52LICENSElicense.txtlicense.txttext/plain; charset=utf-8381https://bonga.unisimon.edu.co/bitstreams/d3c5f770-29df-437d-b6b7-71bf50898c7c/download733bec43a0bf5ade4d97db708e29b185MD53TEXTMortality Rate and Acute Kidney Injury Prevalence Reduction in COVID-19 Critical Patients Treated with Hemoperfusion.pdf.txtMortality Rate and Acute Kidney Injury Prevalence Reduction in COVID-19 Critical Patients Treated with Hemoperfusion.pdf.txtExtracted texttext/plain13139https://bonga.unisimon.edu.co/bitstreams/dbc45d03-8d66-41d7-9cff-6de9b18b73d0/download17f6bb68a68136a4069a6f9234a0700dMD54PDF.pdf.txtPDF.pdf.txtExtracted texttext/plain13139https://bonga.unisimon.edu.co/bitstreams/f0629e4b-89d6-4e73-a7c5-8f2591178432/download17f6bb68a68136a4069a6f9234a0700dMD56THUMBNAILMortality Rate and Acute Kidney Injury Prevalence Reduction in COVID-19 Critical Patients Treated with Hemoperfusion.pdf.jpgMortality Rate and Acute Kidney Injury Prevalence Reduction in COVID-19 Critical Patients Treated with Hemoperfusion.pdf.jpgGenerated Thumbnailimage/jpeg6379https://bonga.unisimon.edu.co/bitstreams/060fb2c6-0e74-4ef5-8375-d4cbde4750a7/download8ed6de63ceec942325b41c3d9259e908MD55PDF.pdf.jpgPDF.pdf.jpgGenerated Thumbnailimage/jpeg6379https://bonga.unisimon.edu.co/bitstreams/d8f47a98-cf43-43bb-8e45-0872bde52b0d/download8ed6de63ceec942325b41c3d9259e908MD5720.500.12442/14485oai:bonga.unisimon.edu.co:20.500.12442/144852024-08-14 21:54:19.141http://creativecommons.org/licenses/by-nc-nd/4.0/Attribution-NonCommercial-NoDerivatives 4.0 Internacionalopen.accesshttps://bonga.unisimon.edu.coRepositorio Digital Universidad Simón Bolívarrepositorio.digital@unisimon.edu.coPGEgcmVsPSJsaWNlbnNlIiBocmVmPSJodHRwOi8vY3JlYXRpdmVjb21tb25zLm9yZy9saWNlbnNlcy9ieS1uYy80LjAvIj48aW1nIGFsdD0iTGljZW5jaWEgQ3JlYXRpdmUgQ29tbW9ucyIgc3R5bGU9ImJvcmRlci13aWR0aDowO3dpZHRoOjEwMHB4OyIgc3JjPSJodHRwczovL2kuY3JlYXRpdmVjb21tb25zLm9yZy9sL2J5LW5jLzQuMC84OHgzMS5wbmciIC8+PC9hPjxici8+RXN0YSBvYnJhIGVzdMOhIGJham8gdW5hIDxhIHJlbD0ibGljZW5zZSIgaHJlZj0iaHR0cDovL2NyZWF0aXZlY29tbW9ucy5vcmcvbGljZW5zZXMvYnktbmMvNC4wLyI+TGljZW5jaWEgQ3JlYXRpdmUgQ29tbW9ucyBBdHJpYnVjacOzbi1Ob0NvbWVyY2lhbCA0LjAgSW50ZXJuYWNpb25hbDwvYT4u |